WORLD HEALTH ORGANIZATION

The global pathological examination market, projected to reach USD 1,466.3 million by 2032 with a CAGR of 20.1%, is driven by chronic disease prevalence, digital pathology advancements, and personalized medicine. Key segments include digital and traditional pathology, anatomic and molecular pathology, and applications in digestive organ pathology. North America leads, while Asia-Pacific shows fastest growth. Telepathology, AI-driven solutions, and emerging markets offer significant opportunities.

UC San Diego researchers analyzed 724 malaria parasite genomes to identify genetic variants conferring drug resistance, aiming to predict antimalarial drug resistance using machine learning. The study, published in *Science*, could streamline early drug development and has broader implications for predicting treatment resistance in other diseases, including cancer.

Technology is revolutionizing healthcare through AI diagnostics, wearable devices, telemedicine, and EHRs, enhancing care quality and efficiency. However, challenges like data privacy and accessibility must be addressed to ensure equitable benefits.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.

MHRA launched a consultation on pre-market regulatory changes for medical devices and IVD devices, addressing International Reliance Scheme, UKCA Marking, IVD devices, and Assimilated EU Law, seeking feedback until 5 January 2025.

A Phase II trial of AstraZeneca’s Fasenra in eosinophilic asthma and COPD exacerbations showed a 45% exacerbation rate with Fasenra vs. 74% with prednisolone, with no fatal AEs. Fasenra was well-tolerated, offering better outcomes than standard care.

GSK's fully liquid Menveo meningococcal vaccine approved by European Commission, simplifying vaccination process against invasive meningococcal disease.

Australian-supported research published in The Lancet, JAMA, and JACC reveals GMRx2, a triple combination pill, significantly more effective at controlling hypertension than dual combinations, potentially revolutionising global hypertension management.

Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, lung transplant, or hospitalization in a Phase 3 trial for PAH patients at high risk of dying, leading to an early trial conclusion. All participants are now offered Winrevair in the SOTERIA extension study.